Introduction {#section1-1533033819829485}
============

Gastric cancer is one of the common malignant tumors and is considered a major public health threat all over the world.^[@bibr1-1533033819829485]^ Nowadays, although the incidence rate of gastric cancer has been decreasing globally, the prognosis of gastric cancer remains poor. Most patients with gastric cancer are from Asia, and more than half patients come from China.^[@bibr2-1533033819829485]^ Although the early-stage gastric cancer is without symptoms, majority of patients have advanced-stage gastric cancer when diagnosed. Moreover, recurrence and metastasis are the common factors that lead to the low level of 5-year survival rate in gastric cancer. It is urgent that the gastric cancer should be diagnosed early. Thus, it is important to explore the potential prognostic biomarkers that can distinguish patients who may benefit from the therapeutic regimens from those who may not.

In recent years, neoadjuvant chemotherapy has been proved to be effective in the treatment of gastric cancer. Many researches have indicated that the neoadjuvant chemotherapy may decrease the tumor stage and increase the R0 resection rate without increasing surgical morbidity and mortality, compared with taking surgical treatment alone.^[@bibr3-1533033819829485]^ The neoadjuvant chemotherapy may result in increased pathological complete response (path CR) with tolerable side effects and lower negative pathological nodes.^[@bibr4-1533033819829485]^ For the past several decades, the neotype chemotherapeutics have been emerging markedly, and the S-1 plus oxaliplatin (SOX) and oxaliplatin and capecitabine (XELOX) regimens are commonly used in clinical practice.^[@bibr5-1533033819829485],[@bibr6-1533033819829485]^ Radical surgery with D2 lymph--node dissection and neoadjuvant chemotherapy regimens have significantly improved the survival rate of patients with gastric cancer.^[@bibr7-1533033819829485]^ Thus, it is of importance to look for more precise biomarkers to improve better survival outcome for patients with gastric cancer.

Cancer-related inflammation is considered the seventh hallmark of cancer and acts as a main component and plays a critical role in cancer development and progression.^[@bibr8-1533033819829485]^ Nowadays, it is well known that inflammation plays pivotal roles in tumor carcinogenesis and progression.^[@bibr9-1533033819829485],[@bibr10-1533033819829485]^ Recently, the systemic inflammatory response (SIR) is closely correlated with prognosis of many tumors. Tumor--inflammation interaction might represent a possible therapeutic target for the neoplastic therapy. Moreover, the relationship between SIR and malignant tumors has been hotly researched. Accumulated studies have reported that C-reactive protein (CRP), white blood cell, neutrophil (N), lymphocyte, monocyte, platelet counts, as well as neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) might influence the tumor carcinogenesis and metastasis.^[@bibr11-1533033819829485],[@bibr12-1533033819829485]^

Studies have reported that the PLR is a useful predictor in gastric cancer.^[@bibr13-1533033819829485],[@bibr14-1533033819829485]^ However, the PLR is described rarely in patients undergoing neoadjuvant chemotherapy for gastric carcinoma, especially receiving SOX or XELOX neoadjuvant chemotherapy regimen. In this study, 91 patients with gastric cancer receiving the regimens were enrolled. The aim of the present study is to evaluate the prognostic significance of PLR in patients with gastric cancer receiving SOX or XELOX neoadjuvant chemotherapy regimen.

Materials and Methods {#section2-1533033819829485}
=====================

Patient Selection {#section3-1533033819829485}
-----------------

We retrospectively enrolled 91 patients who were treated at Harbin Medical University Cancer Hospital between August 2008 and September 2015. All patients had stage II/III gastric carcinoma and are treated with neoadjuvant chemotherapy. All cases were diagnosed and confirmed gastric cancer in accordance with pathological evidence, and the clinical stage was determined as II/III according to tumor--node--metastasis (TNM) staging system.^[@bibr15-1533033819829485]^ Our study was approved by Harbin Medical University Cancer Hospital Ethics Committee (approval no. KY2013-05). All patients provided written informed consent prior to enrollment in the study. All procedures were performed in accordance with the standards of the 1964 Helsinki Declaration and its later amendments. The clinical and demographic data were extracted from the patients' medical records. Inclusion criteria were as follows: (1) histologically confirmed, locally advanced gastric cancer; (2) patients with a good performance status, with Eastern Cooperative Oncology Group performance status ranging from 0 to 2 and Karnofsky performance status ≥80; (3) survival time for more than 3 months; and (4) without chemoradiation, targeted therapy, Chinese traditional treatment, and so forth. Exclusion criteria were as follows: (1) with another malignant disease or distant metastases; (2) with any form of acute and chronic inflammatory disease; (3) serious complications, such as lung infection, active bleeding, and intestinal obstruction; and (4) blood transfusion within a month before neoadjuvant chemotherapy.

Treatment Protocols {#section4-1533033819829485}
-------------------

The SOX regimen consisted of oxaliplatin 130 mg/m^2^ (intravenous infusion administered in 500 mL of 5% glucose over a period of 2 hours) combined with S-1 60 mg (orally administered twice a day for 14 days). The XELOX regimen consisted of oxaliplatin 130 mg/m^2^ (intravenous infusion administered in 500 mL of 5% glucose over a period of 2 hours) combined with capecitabine 1500 mg (orally administered twice a day for 14 days). A cycle of the 2 regimens was repeated every 3 weeks.

Response Evaluation {#section5-1533033819829485}
-------------------

The treatment efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors guidelines.^[@bibr16-1533033819829485]^ The clinical response included 4 groups: CR, partial response (PR), stable disease (SD), and progression of disease (PD). Pathological CR was defined as the absence of tumor cells in primary site. The CR and PR were defined as clinical objective response, and the SD or PD as nonclinical response.

Peripheral Venous Blood Sample {#section6-1533033819829485}
------------------------------

Peripheral venous blood samples were routinely obtained and measured within 1 week before neoadjuvant chemotherapy treatment. Hematological parameters were analyzed by XE-2100 hematology analyzer (Sysmex, Kobe, Japan).

Follow-Up {#section7-1533033819829485}
---------

All patients were routinely followed up in inpatient and outpatient every 3 months during the first 2 years after surgery, every 6-month interval thereafter, and until death. Follow-up assessments included laboratory tests, physical examination, multislice computed tomography, gastroscopy, and some other examinations as it fits. Disease-free survival (DFS) is defined as the time from surgery to relapse (local recurrence and distant metastases). Overall survival (OS) is defined as the time from surgery to death for any cause or last follow-up. Follow-up was terminated on December 3, 2016.

Statistical Analysis {#section8-1533033819829485}
--------------------

Statistical analyses were performed by using the SPSS software (version 17.0; SPSS Inc, Chicago, Illinois). The optimal cutoff value for PLR was calculated by using receiver operating characteristic (ROC) curve analyses. The area under the curve (AUC) was used to assess the predictive value. The ratio closest to the point with maximum sensitivity and specificity was defined as the optimal cutoff value. The differences in clinicopathological database of patients were analyzed using χ^2^ test or Fisher exact test. The patients' baseline characteristics were expressed as the mean ± standard error for the qualitative variables and compared using Student *t* test. The DFS and OS were compared using Kaplan-Meier method and log-rank test. The independent prognostic factors and prognostic value of the PLR were assessed by univariate and multivariate Cox proportional hazards regression model. Two-tailed *P* \<0.05 was considered to indicate a statistically significant difference.

Results {#section9-1533033819829485}
=======

Demographic and Clinicopathological Characteristics of Patients {#section10-1533033819829485}
---------------------------------------------------------------

We used the ROC curve to determine an optimal cutoff value of the PLR. The AUC of PLR was 0.566, and the optimal cutoff value was 162. The patients were stratified into 2 groups by the optimal cutoff value of PLR: a low PLR group (PLR \<162) and a high PLR group (PLR ≥162). The baseline demographic and clinicopathological characteristics of enrolled 91 patients, 70 males and 21 females with a median age of 57 years (range 32-73 years), were listed in [Table 1](#table1-1533033819829485){ref-type="table"}. The median body mass index (BMI) was 22.32, ranging from 17.06 to 34.08. We found that patients with low baseline PLR level were more likely to improve demographic and clinicopathological characteristics, including BMI (χ^2^ = 4.862, *P* =0 .027), platelet (χ^2^ = 31.187, *P \<* 0.001), lymphocyte (χ^2^ = 4.299, *P* = 0.038).

###### 

Demographic and Clinicopathological Characteristics of 91 Patients With Advanced Gastric Cancer.

![](10.1177_1533033819829485-table1)

  Parameters                                          Low PLR \<162   High PLR ≥162   χ^2^/*t*   *P* Value
  -------------------------------------- ------------ --------------- --------------- ---------- -----------
  Cases (n)                              91           40              51                         
  Age (years)                                                                         0.266      0.606
   \<57                                  45 (49.5%)   21 (52.5%)      24 (47.1%)                 
   ≥57                                   46 (50.5%)   19 (47.5%)      27 (52.9%)                 
  Gender                                                                              0.381      0.537
   Male                                  70 (76.9%)   32 (80.0%)      38 (74.5%)                 
   Female                                21 (23.1%)   8 (20.0%)       13 (25.5%)                 
  BMI                                                                                 4.862      0.027
   \<22.32                               45 (49.5%)   25 (62.5%)      20 (39.2%)                 
   ≥22.32                                46 (50.5%)   15 (37.5%)      31 (60.8%)                 
  ABO blood type                                                                      4.543      0.235^a^
   A                                     23 (25.3%)   12 (30.0%)      11 (21.6%)                 
   B                                     32 (35.2%)   17 (42.5%)      15 (29.4%)                 
   O                                     27 (29.7%)   9 (22.5%)       18 (35.3%)                 
   AB                                    9 (9.9%)     2 (5.0%)        7 (13.7%)                  
  Blood pressure (before chemotherapy)                                                           
   High value                            126 ± 21     128 ± 23        124 ± 20        0.954      0.343
   Low value                             77 ± 12      78 ± 14         76 ± 11         0.857      0.394
  Blood pressure (before surgery)                                                                
   High value                            123 ± 15     123 ± 13        122 ± 15        0.407      0.685
   Low value                             77 ± 9       78 ± 9          75 ± 9          1.750      0.084
  Chemotherapy regimen                                                                1.289      0.256
   SOX                                   35 (38.5%)   18 (45.0%)      17 (33.3%)                 
   XELOX                                 56 (61.5%)   22 (55.0%)      34 (66.7%)                 
  Radical resection                                                                   3.066      0.216
   R0                                    51 (56.0%)   26 (65.0%)      25 (49.0%)                 
   R1                                    21 (23.1%)   6 (15.0%)       15 (29.4%)                 
   R2                                    19 (20.9%)   8 (20.0%)       11 (21.6%)                 
  Type of surgery                                                                     0.232      1.000^a^
   Distal gastrectomy                    52 (57.1%)   23 (57.5%)      29 (56.9%)                 
   Proximal gastrectomy                  6 (6.6%)     3 (7.5%)        3 (5.9%)                   
   Total gastrectomy                     33 (36.3%)   14 (35.0%)      19 (37.2%)                 
  Differentiation                                                                     1.159      0.549^a^
   Poorly differentiated                 54 (59.3%)   24 (60.0%)      30 (58.8%)                 
   Moderately differentiated             32 (35.2%)   15 (37.5%)      17 (33.3%)                 
   Well differentiated                   5 (5.5%)     1 (2.5%)        4 (7.9%)                   
  Primary tumor site                                                                  2.118      0.374^a^
   Upper 1/3                             11 (12.1%)   4 (10.0%)       7 (13.7%)                  
   Middle 1/3                            31 (34.1%)   11 (27.5%)      20 (39.2%)                 
   Low 1/3                               49 (53.8%)   25 (62.5%)      24 (47.1%)                 
  Pathology                                                                           1.881      0.626^a^
   Normal (Tis)                          5 (5.5%)     3 (7.5%)        2 (4.0%)                   
   Adenocarcinoma                        63 (69.2%)   26 (65.0%)      37 (72.6%)                 
   Mucinous carcinoma                    10 (11.0%)   4 (10.0%)       6 (11.8%)                  
   Signet ring cell carcinoma            12 (13.2%)   7 (17.5%)       5 (9.8%)                   
   Others                                1 (1.1%)     0 (0.0%)        1 (2.0%)                   
  Clinical TNM classification                                                                    
   T stage                                                                                       1.000^a^
    T3                                   6 (6.6%)     3 (7.5%)        3 (5.9%)                   
    T4                                   85 (93.4%)   37 (92.5%)      48 (94.1%)                 
   N stage                                                                            0.432      0.806
    N0                                   24 (26.4%)   11 (27.5%)      13 (25.5%)                 
    N1                                   51 (56.0%)   21 (52.5%)      30 (58.8%)                 
    N2                                   16 (17.6%)   8 (20.0%)       8 (15.7%)                  
   TNM stage                                                                                     0.190^a^
    II                                   2 (2.2%)     2 (5.0%)        0 (0.0%)                   
    III                                  89 (97.8%)   38 (95.0%)      51 (100.0%)                
  Pathological TNM classification                                                                
   T stage                                                                            1.515      0.736^a^
    Tis                                  5 (5.5%)     3 (7.5%)        2 (3.9%)                   
    T1                                   7 (7.7%)     3 (7.5%)        4 (7.8%)                   
    T2                                   14 (15.4%)   5 (12.5%)       9 (17.7%)                  
    T3                                   43 (47.3%)   21 (52.5%)      22 (43.1%)                 
    T4                                   22 (24.2%)   8 (20.0%)       14 (27.5%)                 
   N stage                                                                            2.623      0.623
    N0                                   24 (26.4%)   11 (27.5%)      13 (25.5%)                 
    N1                                   23 (25.3%)   13 (32.5%)      10 (19.6%)                 
    N2                                   15 (16.5%)   5 (12.5%)       10 (19.6%)                 
    N3                                   29 (31.8%)   11 (27.5%)      18 (35.3%)                 
   TNM stage                                                                          1.001      0.923^a^
    Tis                                  5 (5.5%)     3 (7.5%)        2 (3.9%)                   
    I                                    9 (9.9%)     4 (10.0%)       5 (9.8%)                   
    II                                   29 (31.8%)   14 (35.0%)      15 (29.4%)                 
    III                                  45 (49.5%)   18 (45.0%)      27 (53.0%)                 
    IV                                   3 (3.3%)     1 (2.5%)        2 (3.9%)                   
  Total lymph nodes                                                                   0.566      0.452
   \<27                                  45 (49.5%)   18 (45.0%)      27 (52.9%)                 
   ≥27                                   46 (50.5%)   22 (55.0%)      24 (47.1%)                 
  Positive lymph nodes                                                                4.000      0.135
   0                                     25 (27.5%)   11 (27.5%)      14 (27.5%)                 
   \<3                                   19 (20.9%)   12 (30.0%)      7 (13.7%)                  
   ≥3                                    47 (51.6%)   17 (42.5%)      30 (58.8%)                 
  HER-2                                                                               0.295      0.587
   0-+                                   54 (59.3%)   25 (62.5%)      29 (56.9%)                 
   ++-+++                                37 (40.7%)   15 (37.5%)      22 (43.1%)                 
  Platelet (P)                                                                        31.187     \<0.001
   \<294                                 45 (49.5%)   33 (82.5%)      12 (23.5%)                 
   ≥294                                  46 (50.5%)   7 (17.5%)       39 (76.5%)                 
  Lymphocyte (L)                                                                      4.299      0.038
   \<1.68                                43 (47.3%)   14 (35.0%)      29 (56.9%)                 
   ≥1.68                                 48 (52.7%)   26 (65.0%)      22 (43.1%)                 
  Response                                                                            1.534      0.725^a^
   CR                                    5 (5.5%)     3 (7.5%)        2 (3.9%)                   
   PR                                    65 (71.4%)   28 (70.0%)      37 (72.6%)                 
   SD                                    7 (7.7%)     4 (10.0%)       3 (5.8%)                   
   PD                                    14 (15.4%)   5 (12.5%)       9 (17.7%)                  

Abbreviations: BMI, body mass index; CR, complete response; N, neutrophil; PD, progression of disease PLR, platelet-to-lymphocyte ratio; PR, partial response; SD, stable disease; SOX, S-1 plus oxaliplatin; TNM, tumor--node--metastasis; XELOX, oxaliplatin and capecitabine.

^a^Performed using the Fisher exact test.

Univariate and Multivariate Cox Regression Survival Analyses {#section11-1533033819829485}
------------------------------------------------------------

As regard to DFS, based on univariate analysis, the significant prognostic factors were age, ABO blood type, radical resection, type of surgery, differentiation, primary tumor site, pathological TNM stage, platelet, lymphocyte, and PLR. Based on the multivariate Cox regression analysis, the factors associated with DFS were age, radical resection, type of surgery, differentiation, primary tumor site, pathological TNM stage, platelet, lymphocyte, and PLR ([Table 2](#table2-1533033819829485){ref-type="table"}). Based on univariate analysis, the significant prognostic factors for OS were age, radical resection, type of surgery, differentiation, primary tumor site, pathological N stage, pathological TNM stage, platelet, lymphocyte, and PLR. Based on the multivariate Cox regression analysis, the factors associated with OS were age, radical resection, type of surgery, differentiation, primary tumor site, pathological N stage, pathological TNM stage, platelet, and PLR ([Table 2](#table2-1533033819829485){ref-type="table"}).

###### 

Univariate and Multivariate Cox Regression Analyses of DFS and OS in 91 Patients With Advanced Gastric Cancer.

![](10.1177_1533033819829485-table2)

  Parameters                                        DFS                       OS                                                                                                      
  ------------------------------------------------- ------------------------- --------- ----------------------- --------- ------------------------- --------- ----------------------- ---------
  Age (years)                                                                 0.011                             0.027                               0.006                             0.020
   \<57                                             1 (reference)                       1 (reference)                     1 (reference)                       1 (reference)           
   ≥57                                              0.304 (0.121-0.764)                 0.462 (0.234-0.914)               0.271 (0.107-0.683)                 0.483 (0.261-0.894)     
  Gender                                                                      0.185                                                                 0.181                             
   Male                                             1 (reference)                                                         1 (reference)                                               
   Female                                           2.346 (0.665-8.274)                                                   2.251 (0.685-7.398)                                         
  BMI                                                                         0.690                                                                 0.768                             
   \<22.32                                          1 (reference)                                                         1 (reference)                                               
   ≥22.32                                           1.198 (0.493-2.914)                                                   1.141 (0.474-2.749)                                         
  ABO blood type                                                              0.045                             0.069                               0.236                             
   A                                                1 (reference)                       1 (reference)                     1 (reference)                                               
   B                                                0.198 (0.036-1.091)                 0.217 (0.064-0.739)               0.275 (0.045-1.662)                                         
   O                                                1.118 (0.221-5.663)                 0.634 (0.222-1.812)               0.955 (0.197-4.632)                                         
   AB                                               1.083 (0.211-5.567)                 0.430 (0.145-1.278)               0.973 (0.200-4.744)                                         
  Chemotherapy regimen                                                        0.397                                                                 0.101                             
   SOX                                              1 (reference)                                                         1 (reference)                                               
   XELOX                                            0.645 (0.234-1.780)                                                   0.431 (0.158-1.178)                                         
  Radical resection                                                           \<0.001                           \<0.001                             \<0.001                           \<0.001
   R0                                               1 (reference)                       1 (reference)                     1 (reference)                       1 (reference)           
   R1                                               0.069 (0.022-0.216)                 0.212 (0.107-0.420)               0.025 (0.007-0.088)                 0.137 (0.067-0.281)     
   R2                                               0.132 (0.034-0.506)                 0.342 (0.158-0.741)                                                   0.247 (0.112-0.541)     
  Type of surgery                                                             0.007                             0.009                               \<0.001                           0.001
   Distal gastrostomy                               1 (reference)                       1 (reference)                     1 (reference)                       1 (reference)           
   Proximal gastrostomy                             7.889 (2.115-29.498)                5.420 (1.567-18.752)              16.779 (4.356-64.633)               8.314 (2.687-25.727)    
   Total gastrostomy                                11.205 (1.057-118.803)              11.239 (1.595-79.199)             17.996 (1.628-198.948)              10.026 (1.458-68.960)   
  Differentiation                                                             0.001                             0.003                               0.002                             0.013
   Poorly differentiated                            1 (reference)                       1 (reference)                     1 (reference)                       1 (reference)           
   Moderately differentiated                        51.745 (6.039-443.373)              9.880 (2.280-42.804)              39.273 (4.999-308.532)              6.843 (1.827-25.634)    
   Well differentiated                              11.721 (1.640-83.761)               4.000 (0.938-17.059)              18.851 (2.901-122.490)              4.018 (1.043-15.474)    
  Primary tumor site                                                          0.001                             0.009                               \<0.001                           0.005
   Upper 1/3                                        1 (reference)                       1 (reference)                     1 (reference)                       1 (reference)           
   Middle 1/3                                       26.380 (3.996-174.154)              6.242 (1.563-24.924)              27.713 (4.014-191.332)              4.688 (1.366-16.093)    
   Low 1/3                                          14.535 (2.919-72.359)               6.435 (1.735-23.865)              24.647 (4.785-126.948)              6.520 (1.974-21.534)    
  Pathology                                                                   0.662                                                                 0.617                             
   Normal (Tis) + adenocarcinoma                    1 (reference)                                                         1 (reference)                                               
   Mucinous + signet ring cell carcinoma + others   1.255 (0.453-3.478)                                                   1.309 (0.455-3.770)                                         
  Clinical TNM classification                                                                                                                                                         
   T stage                                                                    0.170                                                                 0.177                             
    T3                                              1 (reference)                                                         1 (reference)                                               
    T4                                              0.130 (0.007-2.394)                                                   0.148 (0.009-2.363)                                         
   N stage                                                                    0.584                                                                 0.495                             
    N0                                              1 (reference)                                                         1 (reference)                                               
    N1                                              0.516 (0.146-1.821)                                                   0.483 (0.132-1.775)                                         
    N2                                              0.743 (0.237-2.330)                                                   0.550 (0.173-1.752)                                         
   TNM stage                                                                  0.126                                                                 0.075                             
    II                                              1 (reference)                                                         1 (reference)                                               
    III                                             26.759 (0.398-1798.221)                                               35.945 (0.699-1849.658)                                     
  Pathological TNM classification                                                                                                                                                     
   T stage                                                                    0.140                                                                 0.435                             
    Tis + T1                                        1 (reference)                                                         1 (reference)                                               
    T2                                              0.898 (0.046-17.496)                                                  0.237 (0.013-4.429)                                         
    T3                                              6.141 (0.867-43.498)                                                  1.624 (0.270-9.770)                                         
    T4                                              3.225 (0.741-14.031)                                                  1.310 (0.283-6.055)                                         
   N stage                                                                    0.057                                                                 0.017                             0.010
    N0                                              1 (reference)                                                         1 (reference)                       1 (reference)           
    N1                                              0.191 (0.008-4.763)                                                   0.081 (0.003-1.990)                 0.156 (0.037-0.654)     
    N2                                              1.521 (0.091-25.302)                                                  0.929 (0.057-15.107)                1.078 (0.400-2.901)     
    N3                                              1.772 (0.572-5.485)                                                   2.339 (0.734-7.454)                 2.278 (1.020-5.087)     
   TNM stage                                                                  0.024                             \<0.001                             0.035                             \<0.001
    Tis + I                                         1 (reference)                       1 (reference)                     1 (reference)                       1 (reference)           
    II                                              1.983 (0.245-16.039)                2.115 (0.458-9.755)               0.849 (0.093-7.716)                 1.589 (0.341-7.408)     
    III                                             6.168 (0.677-56.197)                7.981 (1.896-33.590)              2.606 (0.269-25.260)                6.685 (1.593-28.060)    
    IV                                              16.344 (1.438-185.706)              12.422 (1.946-79.282)             7.434 (0.705-78.387)                14.815 (2.294-95.680)   
  Total lymph nodes                                                           0.791                                                                 0.647                             
   \<27                                             1 (reference)                                                         1 (reference)                                               
   ≥27                                              1.133 (0.449-2.862)                                                   1.235 (0.500-3.051)                                         
  Positive lymph nodes                                                        0.762                                                                 0.992                             
   \<3                                              1 (reference)                                                         1 (reference)                                               
   ≥3                                               1.462 (0.125-17.084)                                                  0.988 (0.084-11.616)                                        
  HER-2                                                                       0.445                                                                 0.789                             
   0-+                                              1 (reference)                                                         1 (reference)                                               
   ++-+++                                           1.398 (0.592-3.303)                                                   1.127 (0.469-2.712)                                         
  Platelet (P)                                                                \<0.001                           0.004                               \<0.001                           \<0.001
   \<294                                            1 (reference)                       1 (reference)                     1 (reference)                       1 (reference)           
   ≥294                                             13.979 (3.172-61.602)               3.947 (1.543-10.096)              23.553 (5.352-103.658)              5.949 (2.356-15.017)    
  Lymphocyte (L)                                                              0.003                             0.008                               0.019                             0.077
   \<1.68                                           1 (reference)                       1 (reference)                     1 (reference)                       1 (reference)           
   ≥1.68                                            0.165 (0.050-0.541)                 0.353 (0.163-0.765)               0.271 (0.091-0.808)                 0.558 (0.293-1.064)     
  PLR                                                                         0.002                             0.025                               0.002                             0.010
   \<162                                            1 (reference)                       1 (reference)                     1 (reference)                       1 (reference)           
   ≥162                                             0.133 (0.037-0.483)                 0.345 (0.135-0.877)               0.151 (0.045-0.508)                 0.304 (0.123-0.752)     

Abbreviations: BMI, body mass index; CI, confidence interval; DFS, disease-free survival; N, neutrophil; OR, odds ratio; OS, overall survival; PLR, platelet-to-lymphocyte ratio; TNM, tumor--node--metastasis; SOX, S-1 plus oxaliplatin; XELOX, oxaliplatin and capecitabine.

Survival and Evaluation of the Prognostic Factors {#section12-1533033819829485}
-------------------------------------------------

Univariate and multivariate Cox proportional hazards regression model were used to evaluate the independent prognostic factors and prognostic value of the PLR. We found that PLR had prognostic significance using the cutoff value of 162 on DFS and OS before neoadjuvant chemotherapy. In univariate analysis, low PLR was associated with prolonged DFS and OS (*P* = 0.002, hazard ratio \[HR\]: 0.133, 95% confidence interval \[CI\]: 0.037-0.483; *P* = 0.002, HR: 0.151, 95% CI: 0.045-0.508, respectively). In multivariate analysis, low PLR was associated with prolonged DFS and OS (*P* = 0.025, HR: 0.345, 95% CI: 0.135-0.877; *P* = 0.010, HR: 0.304, 95% CI: 0.123-0.752, respectively; [Table 2](#table2-1533033819829485){ref-type="table"}). The mean DFS and OS for patients with low PLR were 47.33 and 51.21 months, respectively. The mean DFS and OS for patients with high PLR were 33.62 and 36.80 months, respectively. By using log-rank test, the mean DFS and OS time for patients with low PLR were longer than those with high PLR (χ^2^ = 2.777, *P* = 0.096 and χ^2^ = 1.793, *P* = 0.181, respectively; [Figure 1A and B](#fig1-1533033819829485){ref-type="fig"}).

![Disease-free survival (DFS) and overall survival (OS) of patients with gastric cancer. (A) Kaplan-Meier analysis of DFS for the platelet-to-lymphocyte ratio (PLR) of all patients with gastric cancer; (B) Kaplan-Meier analysis of OS for the PLR of all patients with gastric cancer.](10.1177_1533033819829485-fig1){#fig1-1533033819829485}

Survival and Evaluation of the Prognostic Significance of PLR {#section13-1533033819829485}
-------------------------------------------------------------

For all enrolled patients, the 1-, 3-, and 5-year rates of DFS and OS were 75.8% (69/91), 23.1% (21/91), and 7.7% (7/91) and 87.9% (80/91), 26.4% (24/91), and 11.0% (10/91), respectively. Moreover, the 1-, 3-, and 5-year rates of DFS and OS in low PLR were 82.5% (33/40), 27.5% (11/40), and 10.0% (4/40) and 90.0% (36/40), 27.5% (11/40), and 15.0% (6/40), respectively. The 1-, 3-, and 5-year rates of DFS and OS in high PLR were 70.6% (36/51), 19.6% (10/51), and 5.9% (3/51) and 86.3% (44/51), 25.5% (13/51), and 7.8% (4/51), respectively. Meanwhile, the patients with low PLR had better 1-, 3-, and 5-year rates of DFS and OS than those with high PLR. Patients with gastric cancer who had lower PLR were more likely to have longer DFS and OS ([Table 3](#table3-1533033819829485){ref-type="table"}, [Figure 2A and B](#fig2-1533033819829485){ref-type="fig"}).

###### 

One-, 3-, and 5-year DFS and OS Rates of the 91 Patients With Advanced Gastric Cancer.

![](10.1177_1533033819829485-table3)

  Parameters   Cases (n)   DFS         OS                                             
  ------------ ----------- ----------- ----------- ---------- ----------- ----------- -----------
  Total        91          69 (75.8)   21 (23.1)   7 (7.7)    80 (87.9)   24 (26.4)   10 (11.0)
  Low PLR      40          33 (82.5)   11 (27.5)   4 (10.0)   36 (90.0)   11 (27.5)   6 (15.0)
  High PLR     51          36 (70.6)   10 (19.6)   3 (5.9)    44 (86.3)   13 (25.5)   4 (7.8%)
  χ^2^                     1.735       0.787                              0.047       
  *P* value                0.188       0.375       0.695^a^   0.750^a^    0.829       0.325^a^

Abbreviations: DFS, disease-free survival; OS, overall survival; PLR, platelet-to-lymphocyte ratio.

^a^Fisher exact test.

![The 1-, 3-, and 5-year rates of DFS and OS in patients with gastric cancer. (A) The 1-, 3-, and 5-year rates of DFS for the PLR of all patients with gastric cancer; (B) the 1-, 3-, and 5-year rates of OS for the PLR of all patients with gastric cancer. DFS indicates disease-free survival; PLR, platelet-to-lymphocyte ratio; OS, overall survival.](10.1177_1533033819829485-fig2){#fig2-1533033819829485}

Association of Platelet Counts and PLR in Patients With Gastric Cancer {#section14-1533033819829485}
----------------------------------------------------------------------

With low platelet counts, the median DFS and OS for patients with low PLR were 23.73 and 26.87 months and that of for patients with high PLR were 16.50 and 16.50 months, respectively. The results indicated that patients with low PLR had longer DFS and OS than those with high PLR and low platelet counts (χ^2^ = 1.283, *P* = 0.257 and χ^2^ = 1.680, *P* = 0.195, respectively; [Figure 3A and B](#fig3-1533033819829485){ref-type="fig"}). With high platelet counts, the median DFS and OS for patients with low PLR were 32.54 and 36.40 months and that of for patients with high PLR were 20.47 and 26.80 months, respectively. Meanwhile, patients with low PLR had longer DFS and OS than those with high PLR and high platelet counts (χ^2^ = 5.758, *P* = 0.016 and χ^2^ = 5.184, *P* = 0.023, respectively; [Figure 3C and D](#fig3-1533033819829485){ref-type="fig"}).

![Disease-free survival (DFS) and overall survival (OS) for the platelet-to-lymphocyte ratio (PLR) of patients with gastric cancer in platelet counts. (A) Kaplan-Meier analysis of DFS for the PLR of patients with gastric cancer in low platelet counts; (B) Kaplan-Meier analysis of OS for the PLR of patients with gastric cancer in low platelet counts; (C) Kaplan-Meier analysis of DFS for the PLR of patients with gastric cancer in high platelet counts; (D) Kaplan-Meier analysis of OS for the PLR of patients with gastric cancer in high platelet counts.](10.1177_1533033819829485-fig3){#fig3-1533033819829485}

Association of Lymphocyte Counts and PLR in Patients With Gastric Cancer {#section15-1533033819829485}
------------------------------------------------------------------------

With low lymphocyte counts, the median DFS and OS for patients with low PLR were 16.40 and 21.03 months and that of for patients with high PLR were 26.80 and 29.37 months, respectively. The results indicated that patients with high PLR had longer DFS and OS than those with low PLR and low lymphocyte counts (χ^2^ = 0.844, *P* = 0.358 and χ^2^ = 0.997, *P* = 0.318, respectively; [Figure 4A and B](#fig4-1533033819829485){ref-type="fig"}). With high lymphocyte counts, the median DFS and OS for patients with low PLR were 57.94 and 62.52 months and that of for patients with high PLR were 26.87 and 30.91 months, respectively. Patients with low PLR had longer DFS and OS than those with high PLR and high lymphocyte counts (χ^2^ = 9.130, *P* = 0.003 and χ^2^ = 6.867, *P* = 0.009, respectively; [Figure 4C and D](#fig4-1533033819829485){ref-type="fig"}).

![Disease-free survival (DFS) and overall survival (OS) for the platelet-to-lymphocyte ratio (PLR) of patients with gastric cancer in lymphocyte counts. (A) Kaplan-Meier analysis of DFS for the PLR of patients with gastric cancer in low lymphocyte counts; (B) Kaplan-Meier analysis of OS for the PLR of patients with gastric cancer in low lymphocyte counts; (C) Kaplan-Meier analysis of DFS for the PLR of patients with gastric cancer in high lymphocyte counts; (D) Kaplan-Meier analysis of OS for the PLR of patients with gastric cancer in high lymphocyte counts.](10.1177_1533033819829485-fig4){#fig4-1533033819829485}

Association of SOX or XELOX Regimen and PLR in Patients With Gastric Cancer {#section16-1533033819829485}
---------------------------------------------------------------------------

In order to further investigate the prognostic efficiency of PLR, the PLR was analyzed by SOX or XELOX regimen. With SOX regimen, the results indicated that the mean DFS and OS for patients with low PLR were 40.83 and 41.44 months and that of for patients with high PLR were 29.41 and 39.38 months, respectively. We found that patients with low PLR had longer DFS and OS than those with high PLR in receiving SOX regimen (χ^2^ =0.932, *P* = 0.334 and χ^2^ =0.251, *P* = 0.617, respectively; [Figure 5A and B](#fig5-1533033819829485){ref-type="fig"}). With XELOX regimen, the results indicated that the mean DFS and OS for patients with low PLR were 42.05 and 46.38 months and that of for patients with high PLR were 31.26 and 33.92 months, respectively. We found that patients with low PLR had longer DFS and OS than those with high PLR in receiving XELOX regimen (χ^2^ = 1.364, *P* = 0.243 and χ^2^ =0.992, *P* = 0.319, respectively; [Figure 5C and D](#fig5-1533033819829485){ref-type="fig"}).

![Disease-free survival (DFS) and overall survival (OS) for the PLR of patients with gastric cancer in SOX or XELOX regimen. (A) Kaplan-Meier analysis of DFS for the PLR of patients with gastric cancer in SOX regimen; (B) Kaplan-Meier analysis of OS for the PLR of patients with gastric cancer in SOX regimen; (C) Kaplan-Meier analysis of DFS for the PLR of patients with gastric cancer in XELOX regimen; (D) Kaplan-Meier analysis of OS for the PLR of patients with gastric cancer in XELOX regimen. PLR indicates platelet-to-lymphocyte ratio; SOX, S-1 plus oxaliplatin; XELOX, oxaliplatin and capecitabine.](10.1177_1533033819829485-fig5){#fig5-1533033819829485}

Correlation Between PLR and Toxicity Assessment {#section17-1533033819829485}
-----------------------------------------------

For all patients, we analyzed the toxicities after neoadjuvant chemotherapy for 2 cycles. The most common toxicities were hematologic after neoadjuvant chemotherapy. The National Cancer Institute Common Toxicity Criteria grades 1 and 2 anemia, leucopenia, neutropenia, and thrombocytopenia of all cases were recorded in 33/91 (36.3%), 18/91 (19.8%), 21/91 (23.1%), and 4/91 (4.4%), respectively ([Table 4](#table4-1533033819829485){ref-type="table"}). In the present study, there were no chemotherapy-related deaths. To further study the PLR in toxicity assessment, we found that there were no difference using the cutoff value 162 of PLR on leucopenia, neutropenia, and thrombocytopenia (*P \>* 0.05), except anemia (*P \<* 0.05; [Table 4](#table4-1533033819829485){ref-type="table"}).

###### 

Main Toxicities According to NCI-CTC Scale of the Patients With Advanced Gastric Cancer Undergoing Neoadjuvant Chemotherapy.

![](10.1177_1533033819829485-table4)

  Parameters         Number (%)   Low PLR \<162   High PLR ≥162   χ^2^     *P* Value
  ------------------ ------------ --------------- --------------- -------- -----------
  Case (n)           91           40              51                       
  Anemia                                                          10.872   0.001
   Grade 0           58 (63.7)    33 (82.5)       25 (49.0)                
   Grade 1-2         33 (36.3)    7 (17.5)        26 (51.0)                
   Grade 3-4         0 (0.0)      0 (0.0)         0 (0.0)                  
  Leucopenia                                                      2.384    0.123
   Grade 0           73 (80.2)    35 (87.5)       38 (74.5)                
   Grade 1-2         18 (19.8)    5 (12.5)        13 (25.5)                
   Grade 3-4         0 (0.0)      0 (0.0)         0 (0.0)                  
  Neutropenia                                                              0.185^a^
   Grade 0           67 (73.6)    33 (82.5)       34 (66.7)                
   Grade 1-2         21 (23.1)    5 (12.5)        16 (31.3)                
   Grade 3-4         3 (3.3)      2 (5.0)         1 (2.0)                  
  Thrombocytopenia                                                         1.000^a^
   Grade 0           87 (95.6)    38 (95.0)       49 (96.1)                
   Grade 1-2         4 (4.4)      2 (5.0)         2 (3.9)                  
   Grade 3-4         0 (0.0)      0 (0.0)         0 (0.0)                  

Abbreviations: NCI-CTC, National Cancer Institute Common Toxicity Criteria; PLR, platelet-to-lymphocyte ratio.

^a^Fisher exact test.

Discussion {#section18-1533033819829485}
==========

Over the past several decades, with the rapid advances in surgical techniques and multimodal therapy, including chemotherapy, radiotherapy, and targeted therapy, it has greatly prolonged survival time and improved quality of life for patients with gastric cancer.^[@bibr7-1533033819829485]^ Nowadays, neoadjuvant chemotherapy has been advocated to treat the patients with gastric carcinoma, without increasing the postoperative complication, morbidity, and mortality.^[@bibr17-1533033819829485]^ Gastric cancer is one of the diseases with the highest tumor burden. Although some immunological and histological biomarkers associated with poor prognosis in patients with gastric cancer have been identified, these biomarkers largely depend on expensive equipment, difficult technology, time-consuming, and some of them obtained after resection of the primary tumor. Therefore, looking for reliable and affordable prognostic factors in patients with gastric cancer is still needed and ongoing.

Dozens of studies have shown that inflammation is associated with the development and progression of many tumors. As we all know, the tumor cells could influence pro-inflammatory mediators; stimulate the production of CRP; increase peripheral blood N, monocyte, and platelet counts; and decrease lymphocyte counts.^[@bibr18-1533033819829485]^ On the basis of these theories, we may use the cellular components of SIR in peripheral venous blood to predict survival condition and prognosis in many malignancies. However, the mechanisms by which inflammatory response induces a poor outcome remain controversial and poorly understood. Several inflammatory markers in peripheral venous blood as prognostic factors have been studied in some malignant tumors, such as NLR, MLR, PLR, CRP, neutrophil-to-white blood cell ratio, lymphocyte-to-white blood cell ratio, and monocyte-to-white blood cell ratio. Nevertheless, the PLR with regard to DFS and OS in patients with gastric cancer undergoing neoadjuvant chemotherapy of SOX or XELOX regimen has been rarely studied.

Platelets play a key role in tumor development and progression and are associated with poor survival in patients with various types of malignancies, but the potential mechanisms remain unknown.^[@bibr14-1533033819829485]^ Some potential mechanisms may be used to explain that high PLR is associated with poor survival time and prognosis. Platelets can promote increasing angiogenesis via cytokine vascular endothelial growth factor and inhibit the immune system in the bloodstream, such as immune attack.^[@bibr19-1533033819829485]^ Some researches indicate that platelets may help the communication between primary tumor cells and bone remodeling alterations before tumor metastasis.^[@bibr20-1533033819829485]^ Platelets can shield circulating tumor cells (CTCs) from immune attack and destruction by activated platelets, which in turn protect the CTCs from shearing stresses during circulation.^[@bibr21-1533033819829485]^ The lymphocytes are known to play a critical role in tumor immune surveillance and defense of tumor cells by inducing cytotoxic cell death as well as inhibiting proliferation and migration of tumor cells.^[@bibr22-1533033819829485]^ What's more, the increased lymphocyte levels are associated with better prognosis in some solid tumors and can improve the host's anticancer immunity and impair cancer immune surveillance.^[@bibr23-1533033819829485],[@bibr22-1533033819829485]^ Combined with these findings, we found that an increase in the platelet count and decrease in the lymphocyte count in the peripheral venous blood have been related to tumor growth and progression. Therefore, the PLR may help to predict prognosis and reflect the degree of tumor progression in gastric cancer.

The baseline demographic and clinicopathological characteristics of the enrolled 91 patients were analyzed. We found that low baseline PLR was more likely to improve demographic and clinicopathological characteristics, including BMI, platelet, and lymphocyte count. Based on univariate and multivariate Cox regression analysis, the significant prognostic factors predicting improved DFS and OS were age, radical resection, type of surgery, differentiation, primary tumor site, pathological TNM stage, platelet, and PLR. The results demonstrated that PLR had prognostic significance using the cutoff value of 162 on DFS and OS, and the mean DFS and OS time for patients with low PLR were longer than those with high PLR. Meanwhile, the 1-, 3-, and 5-year rates of DFS and OS were analyzed. The results indicated that patients with gastric cancer who had lower PLR were more likely to have longer 1-, 3-, and 5-year rates of DFS and OS.

In addition, we analyzed the PLR in different platelet or lymphocyte counts group. The results also indicated that the patients with low PLR and high lymphocyte counts or low platelet counts had better median DFS and OS. Furthermore, we also analyzed the relationship between PLR and SOX or XELOX regimen. The results indicated that patients with low PLR had longer DFS and OS than those with high PLR in receiving SOX or XELOX regimen. Moreover, the relationship between PLR and toxicity assessment was also analyzed. All patients could tolerate the neoadjuvant chemotherapy toxicities, and the regimens were safety and effective. The most common toxicities were hematologic after neoadjuvant chemotherapy, and there was no difference in PLR in toxicity assessment using the cutoff value of 162 on these toxicities, except anemia.

As far as we are concerned, the PLR value with DFS and OS in patients with gastric cancer undergoing neoadjuvant chemotherapy is rarely discussed. The present study suggests that the PLR level may help to predict prognosis in gastric cancer. With a view to the high gastric cancer morbidity and unbalanced medical condition in China, it is very important to consider these convenient, simple, cheap, reproducible, and noninvasive biomarkers for the prevention and treatment of gastric cancer. Hence, a comprehensive understanding of hematologic parameter may find new targets for individual treatment. Thus, the present study may provide critical information for the treatment of gastric cancer.

All in all, SOX and XELOX regimens were well tolerated by all patients who received. The results of present study explain the reason for elevated PLR enhancing tumor progression, and the low PLR may be a more favorable prognosis. However, there were several limitations in the present study. First, the number of patients was small sample size. Second, this was a retrospective single-center study. Therefore, larger numbers of patients with gastric cancer was treated with neoadjuvant chemotherapy and multicenter study should be enrolled. The differences in the cutoff value of PLR among the studies may be attributable to the differences in the cumulative number of patients and the disease stage among the studies. In our study, whether the cutoff value of 162 for PLR is correct requires further prospective and well-designed, randomized controlled trial investigation.

Conclusions {#section19-1533033819829485}
===========

In conclusion, our data suggest that the PLR qualifies as a convenient, noninvasive, cost-effective, and easily measured prognostic indicator for patients with gastric cancer treated with neoadjuvant chemotherapy. Low PLR may help clinicians to identify those patients who will benefit from neoadjuvant chemotherapy. However, more studies are needed to verify the changes in inflammatory markers in larger groups of patients with gastric cancer.
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AUC

:   area under the curve

BMI

:   body mass index

CI

:   confidence interval

CR

:   complete response

CRP

:   C-reactive protein

CTCs

:   circulating tumor cells

DFS

:   disease-free survival

HR

:   hazard ratio

LMR

:   lymphocyte-to-monocyte ratio

MLR

:   monocyte-to-lymphocyte ratio

N

:   neutrophil

NLR

:   neutrophil-to-lymphocyte ratio

OS

:   overall survival

path CR

:   pathological complete response

PD

:   progression of disease

PLR

:   platelet-to-lymphocyte ratio

PR

:   partial response

ROC

:   receiver operating characteristic

SD

:   stable disease

SIR

:   systemic inflammatory response

SOX

:   S-1 plus oxaliplatin

TNM

:   tumor--node--metastasis

XELOX

:   oxaliplatin and capecitabine
